Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:8/11/2008

roy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. Peregrine recently reported that a Phase II trial assessing the combination of bavituximab and docetaxel in patients with metastatic breast cancer had achieved the pre-specified Stage A primary efficacy endpoint needed to expand the trial to the second stage. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that th
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... EST on Friday, January 6, 2012 at the Millennium Hotel, ... Executive Officer, Patrick G. LePore, and other members of the ... growth strategy, current products and pipelines, and business outlook to ...
... Calif., Dec. 5, 2011  Beyond Lucid Technologies, Inc., ... disaster management, and First Response industries, today announced ... the mHealth Summit, and the publication of a ... connect ambulances with hospitals via telemedicine. ...
Cached Medicine Technology:Beyond Lucid Technologies Advances Telemedicine for EMS Providers 2Beyond Lucid Technologies Advances Telemedicine for EMS Providers 3
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance officers deal with ... the Stark physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices ... Services, Inc. (AIS), will detail which deals are attracting the most government scrutiny ...
(Date:9/4/2015)... NC (PRWEB) , ... September 04, 2015 , ... ... filtration products, has a Labor Day offer that cannot be passed up. ... stock up on necessary air and water filtration product replacements. Take advantage of ...
(Date:9/4/2015)... ... September 04, 2015 , ... Friday night, Chicago lovebirds Jenny McCarthy and Donnie ... of Hope event supporting families affected by autism, raising nearly $250,000. , 150 ... together at the Oscar Swan Inn to support the cause. , McCarthy tugged ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... While bariatric ... to the best practices when preparing for a bariatric procedure, some patients have been ... Apart from the basic instructions typical for many types of surgery that should be ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... TransPack Toon ... Users can choose from wipes and framing transitions in 30 different styles. Presets ... exclusively for Final Cut Pro X. , TransPack Toon features 90 cartoon transitions from ...
Breaking Medicine News(10 mins):Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... Does the consumption of green tea, widely touted ... cells" Authors of a new study being published ... new data that indicates this may be the case. ... a group of naturally occurring chemical substances found in ...
... Dashboard Provides Dynamic, Desktop View of Channel Activity, Enabling ... ... REDWOOD CITY, Calif., Dec. 13 Edge Dynamics, ... life,sciences industry, today announced the new Edge Dynamics Demand ...
... BB&T Insurance,Services, the nation,s seventh largest insurance ... Atlanta operation with the acquisition of Ott &,Company ... & Company is a full-service employee benefits,brokerage providing ... insurance to more than 400 corporate clients., ...
... nation,s leading,supplier of replacement medical repair parts for hospital ... in Ohio by the Case Western,Weatherhead School of Management. ... rate exceeding 1000% and has won the award each ... one of our region,s most prestigious,honors," said PartsSource President ...
... bone marrow transplants , THURSDAY, Dec. 13 (HealthDay News) ... been identified by Stanford University researchers, who said the ... and other blood diseases. , The researchers said this ... a blood-forming stem cell in the bone marrow that,s ...
... Realty Trust, Inc.,(NYSE: BMR ) today announced that ... dividend of $0.31 per share of common stock. The,dividend ... common share., BioMed also announced that its board ... of the company,s 7.375% Series A Cumulative,Redeemable Preferred Stock ...
Cached Medicine News:Health News:Green tea may protect brain cells against Parkinson's disease 2Health News:Edge Dynamics' New Dashboard Unlocks Value of Channel Data Enterprise-wide 2Health News:Edge Dynamics' New Dashboard Unlocks Value of Channel Data Enterprise-wide 3Health News:Edge Dynamics' New Dashboard Unlocks Value of Channel Data Enterprise-wide 4Health News:BB&T Insurance Services to acquire Georgia agency 2Health News:BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: